According to the Alzheimer’s Association, 5.2 million Americans suffer from Alzheimer’s disease and the direct annual costs of the disease are more than $200 billion in the US. While there are a number of potential novel therapeutic approaches that are being evaluated in the clinic for Alzheimer’s, the scientific community’s expectation is that the mechanism of action of these approaches are such that they will have the most impact prior to the onset of symptomatic Alzheimer’s disease. EIP Pharma is developing the first investigational drug that specifically targets the effects of amyloid-beta and inflammation on neuronal and synaptic function. The drug, neflamapimod (previously code named VX-745), is a highly selective oral small molecule inhibitor of the enzyme p38 mitogen-activated protein kinase (MAPK) alpha. Phase 2a clinical studies with neflamapimod in patients with Early Alzheimer's disease were recently completed and the positive results presented at the international Clinical Trials in Alzheimer's Disease (CTAD) conference in December 2016 .
EIP Pharma announces upcoming oral presentations of Alzheimer's clinical trial results with neflamapimod (VX-745)